<DOC>
	<DOCNO>NCT00558272</DOCNO>
	<brief_summary>The purpose study determine effect AZD0530 subject breast cancer prostate cancer metastatic bone disease comparison zoledronic acid .</brief_summary>
	<brief_title>Study Evaluate Safety Effects AZD0530 Prostate Breast Cancer Subjects With Metastatic Bone Disease</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Saracatinib</mesh_term>
	<criteria>Subjects 18 year old Prostate Cancer Breast Cancer Metastatic Bone Disease Have evidence recurrence disease progression At least one radiographically confirm metastatic bone lesion No change cancer therapy least 8 week randomization Have prior exposure bisphosphonate Have hip fracture bilateral hip prothesis fracture kind surgery bone within past 12 month Inadequate renal function low haemoglobin Inadequate liver function demonstrate serum bilirubin ≥2 time upper limit reference range ( ULRR ) alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) ALP ≥2.5 time ULRR ( ≥5 time ULRR presence liver metastasis ) . If bone metastases present liver function otherwise consider adequate investigator elevate ALP exclude patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>metastatic bone disease</keyword>
	<keyword>Subjects breast cancer prostate cancer metastatic bone disease</keyword>
</DOC>